A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma

An Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma

The purpose of this study is to evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (GemOx) versus standard of care (SOC) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have relapsed early (within 1 year) or are primary refractory to first-line therapy. Participants will be randomly assigned in a 1:1 ratio to receive either the Glofitamab-GemOx combination regimen or SOC. The SOC arm consists of investigator's choice of salvage chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) for eligible patients. The primary endpoint of the study is event-free survival (EFS).

Study Overview

• Status: Not yet recruiting
• Conditions: Large B-cell Lymphoma
• Intervention / Treatment: Drug: Obinutuzumab; Drug: Glofitamab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Salvage Chemotherapy (Investigator's Choice); Drug: Autologous Stem Cell Transplantation (ASCT)

• Study Type: Interventional
• Enrollment (Estimated): 96
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Changju Qu; Phone Number: +86-512-67975805; Email: qcj310@163.com

Study Locations

• China
  • Jiangsu
    • Suzhou, Jiangsu, China, 215000
      • The First Affiliated Hospital of Soochow University
      • Contact: Changju Qu; Phone Number: +86-512-67975805; Email: qcj310@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Signed Informed Consent Form.
• Age 18 years or older at the time of signing the Informed Consent Form.
• Histologically proven large B-cell lymphoma (LBCL), including transformation from follicular lymphoma.
• Relapsed or refractory disease after first-line chemoimmunotherapy, defined as refractory disease (no complete remission to first-line therapy, progressive disease as best response, stable disease after 3-4 cycles, or partial response after 6-8 cycles/progression within 12 months) or relapsed disease (complete remission followed by biopsy-proven relapse within 12 months of initiating first-line therapy).
• No known history or suspicion of central nervous system (CNS) involvement by lymphoma.
• Life expectancy of at least 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• At least one bi-dimensionally measurable nodal lesion (1.5 cm or larger) or extranodal lesion (1 cm or larger) as measured on a CT scan.
• Negative HIV test at screening.
• Adequate hematologic function defined as hemoglobin 9.0 g/dL or higher without transfusion in the past 7 days, absolute neutrophil count 1.0 x 10^9/L or higher, and platelet count 75 x 10^9/L or higher.
• Adequate organ function defined as estimated creatinine clearance 60 mL/min or higher, ALT/AST 2.5 times the upper limit of normal (ULN) or lower, and total bilirubin 1.5 mg/dL or lower (or 3 x ULN or lower in subjects with Gilbert's syndrome).
• Cardiac ejection fraction greater than 50%, no evidence of pericardial effusion, and no clinically significant electrocardiogram findings.
• No clinically significant pleural effusion.
• Baseline oxygen saturation greater than 92% on room air.
• Able to understand and complete study-related questionnaires.
• Agreement to remain abstinent or use adequate contraceptive methods for both female and male participants during the treatment period and for the protocol-specified duration after the final dose.

Exclusion Criteria:

• Contraindication to glofitamab components or a history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
• Not eligible for autologous stem cell transplantation (ASCT).
• Prior solid organ transplantation.
• History of Richter's transformation or of indolent disease to diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL).
• Peripheral neuropathy assessed to be greater than Grade 1 at enrollment.
• Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3.
• Use of any investigational therapy for treating cancer within 28 days prior to Cycle 1, any monoclonal antibody within 3 months, or systemic immunotherapeutic agents within 4 weeks or five half-lives (whichever is shorter).
• Prior radiotherapy to the mediastinal or pericardial region.
• History of autologous or allogeneic stem cell transplant.
• Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better, except for alopecia and anorexia.
• Administration of a live, attenuated vaccine within 4 weeks before the first study treatment administration.
• Received more than one line of therapy for DLBCL.
• Corticosteroid use greater than 50 mg/day of prednisone or equivalent for purposes other than lymphoma symptom control.
• Recent major surgery within 4 weeks before the first study treatment.
• History of other malignancy that could affect compliance or interpretation of results, with exceptions for adequately treated low-grade or in situ carcinomas and malignancies in remission for at least 2 years.
• Significant cardiovascular disease, such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 3 months, unstable arrhythmias, or unstable angina.
• Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease, or CNS lymphoma.
• Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
• Current or past history of Waldenstrom macroglobulinemia.
• History or presence of a clinically significant abnormal ECG.
• Known or suspected active infection, reactivation of a latent infection, or any major episode of infection requiring hospitalization or IV antibiotics within 4 weeks of dosing.
• History of severe treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents.
• History of autoimmune disease, with specific protocol-defined exceptions for well-controlled conditions.
• Clinically significant liver disease, including active viral/other hepatitis or cirrhosis.
• Abnormal coagulation laboratory values defined as INR or PT greater than 1.5 x ULN, or PTT/aPTT greater than 1.5 x ULN.
• Suspected active or latent tuberculosis.
• Positive test results for chronic hepatitis B infection (HBsAg positive) or positive test results for hepatitis C with positive HCV RNA.
• Diagnosis with SARS-CoV-2 infection within 30 days prior to first study treatment, or documented infection within 6 months with persistent respiratory symptoms.
• History of progressive multifocal leukoencephalopathy (PML).
• Pregnancy, breastfeeding, or intention of becoming pregnant during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Glofit-GemOx	Drug: Obinutuzumab; A single 1000 mg dose is administered intravenously as pretreatment on Day 1 of Cycle 1 (7 days prior to the first glofitamab dose) to deplete peripheral B-cells and mitigate the risk of cytokine release syndrome (CRS).; Drug: Glofitamab; Glofitamab is administered intravenously using a step-up dosing schedule to mitigate CRS: Cycle 1 Day 8: 2.5 mg. Cycle 1 Day 15: 10 mg. Cycle 2-12 Day 1: 30 mg (target dose). Treatment continues for a maximum of 12 cycles (21-day cycles) or until disease progression/unacceptable toxicity.; Drug: Gemcitabine; Administered intravenously at 1000 mg/m² on Day 2 of Cycle 1, and then on Day 1 or 2 of subsequent cycles (Cycles 2-8).; Drug: Oxaliplatin; Administered intravenously at 100 mg/m² on Day 2 of Cycle 1, and then on Day 1 or 2 of subsequent cycles (Cycles 2-8).
Active Comparator: SoC	Drug: Salvage Chemotherapy (Investigator's Choice); Participants in the SOC arm will receive up to 2 cycles of investigator's choice salvage therapy among the following regimens: ICE ± R, DHAP ± R, GDP ± R, ESHAP ± R, GemOx ± R, or MINE ± R .; Drug: Autologous Stem Cell Transplantation (ASCT); Participants in the SOC arm who achieve a CR or PR after salvage therapy will proceed to ASCT. This includes a conditioning regimen (e.g., BEAM) followed by autologous stem cell rescue and a recovery period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-Free Survival (EFS)	EFS is defined as the time from randomization to the earliest date of disease progression according to the Lugano Classification (2014), commencement of new anti-lymphoma therapy, or death from any cause, as determined by the investigator.	From randomization until the first occurrence of an EFS event (disease progression, new therapy, or death), assessed up to approximately 48 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Response (CR) Rate	The proportion of participants whose best overall response is a CR on PET/CT or diagnostic CT during the study, as determined by the investigator according to the 2014 Lugano Response Criteria.	From randomization to the end of study, up to approximately 48 months.
Objective Response Rate (ORR)	The proportion of participants whose best overall response is a Partial Response (PR) or a Complete Response (CR) during the study, as determined by the investigator according to the 2014 Lugano Response Criteria.	From randomization to the end of study, up to approximately 48 months.
Progression-Free Survival (PFS)	The time from randomization to the first occurrence of disease progression according to the 2014 Lugano Response Criteria or death from any cause, whichever occurs first, as determined by the investigator.	From randomization until disease progression or death, assessed up to approximately 48 months.
Duration of Response (DOR)	The time from the first occurrence of a documented objective response (CR or PR) to disease progression or death from any cause, whichever occurs first.	From the date of first documented objective response until disease progression or death, assessed up to approximately 48 months.
Duration of Complete Response (DOCR)	The time from the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first.	From the date of first documented CR until disease progression or death, assessed up to approximately 48 months.
Overall Survival (OS)	The time from randomization to the date of death from any cause.	From randomization until death, assessed up to approximately 48 months.
Incidence and Severity of Adverse Events (AEs)	Safety and tolerability evaluated by the incidence and severity of AEs. Severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0). Specific events such as CRS, Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and Hemophagocytic Lymphohistiocytosis (HLH) will be graded according to ASTCT criteria.	From the initiation of study treatment up to 35 days after the final dose or initiation of new anti-lymphoma therapy, with long-term monitoring for specific AEs, assessed up to approximately 48 months.
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score	The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/quality of life (QoL) scale, and 6 single items. The first 28 items are scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). The final 2 global health/QoL items are scored on a 7-point scale ranging from 1 ("very poor") to 7 ("excellent"). Higher scores on the global health/QoL and functional scales indicate a better level of functioning and better HRQoL (a better outcome). Conversely, higher scores on the symptom scales/items indicate higher symptom severity (a worse outcome).	Baseline up to approximately 48 months.
Change from Baseline in Functional Assessment of Cancer Therapy-Lymphoma Symptoms Subscale (FACT-Lym LymS) Score	The FACT-Lym LymS assesses health-related quality of life aspects relevant to lymphoma patients using a 15-item lymphoma-specific symptoms scale. Each item is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). Higher total scores are indicative of better health-related quality of life (a better outcome).	Baseline up to approximately 48 months.
Change from Baseline in EuroQoL-5 Dimension-5 Level (EQ-5D-5L) Score	The EQ-5D-5L is a health status questionnaire containing a five-item descriptive system (assessing mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a Visual Analog Scale (VAS). The VAS measures the patient's self-rated health on a vertical scale ranging from 0 ("worst imaginable health state") to 100 ("best imaginable health state"). A published weighting system is used to create a single composite score of the patient's health status. Higher scores on the VAS and the composite utility score indicate a better health status (a better outcome).	Baseline up to approximately 48 months.

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Soochow University

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): June 1, 2030
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: April 16, 2026
• First Submitted That Met QC Criteria: May 14, 2026
• First Posted (Actual): May 20, 2026

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Coordination Complexes; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Oxaliplatin; Gemcitabine; obinutuzumab; glofitamab
• Other Study ID Numbers: ML46548

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No